Wikipedia:Articles for deletion/China Pharmacy


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was keep. (non-admin closure) Garuda3 (talk) 00:01, 9 March 2023 (UTC)

China Pharmacy

 * – ( View AfD View log | edits since nomination)

Non-notable journal. Not indexed in any selective databases, no independent sources. Does not meet WP:NJournals or WP:GNG. Randykitty (talk) 14:04, 1 March 2023 (UTC)
 * Note: This discussion has been included in the list of Academic journals-related deletion discussions. Randykitty (talk) 14:04, 1 March 2023 (UTC)
 * Note: This discussion has been included in the list of China-related deletion discussions. Randykitty (talk) 14:05, 1 March 2023 (UTC)

Keep per the significant coverage in multiple independent reliable sources.  Here are the author affiliations: "QU Qing-hui; ZHANG Xin-yang; Editorial Department of "Northwest Pharmaceutical Journal", School of Pharmacy, Xi’an Jiaotong University; AVIC Xi’an Flight Automatic Control Research Institute". The abstract notes: "Objective To study the high-download papers（download frequency ≥1000） of "China Pharmacy" and the correlation between the download frequency and the citation frequency, so as to provide reference for improving the academic quality and influence of the journal. Methods The annual distribution, number of authors, co-authors, organization type distribution, regional distribution, funding status, and downloads of highdownload papers in "China Pharmacy" from 2000 to 2021 were carried out using China HowNet’s "Chinese Academic Journals（Online Edition）"."  Here are the author affiliations: "FEI Xiao-fan, REN Xue-song, LI Kai-lan, et al. (Department of Pharmacy, First University Hospital, West China University of Medical Sciences, Chengdu 610041, China)". The abstract notes (bolding added for emphasis): "Objective:To realize the quality of the ethics of the randomized controlled trials in Chinese Pharmacy from 1990 to 2000.Methods:It was checked over page-by-page the control trials of clinical therapeutic studies in Chinese Pharmacy from 1990 to 2000 to identify strictly randomized controlled tests（RCT）and controlled clinical tests（CCT）according to the criteria of the handbook of Cochrane collaboration in 1997.Result: A trial of 63 articles on clinical trials was published in 66 issues covered 11 volumes of the Chinese Pharmacy,among which,there were 1 issues of RCT. Conclusion; There still exist many problems and urge the clinical workers to adopt RCT and blind trial as more as possible and guarantee RCTs to be precise as it demands" There is sufficient coverage in reliable sources to allow China Pharmacy to pass Notability, which requires "significant coverage in reliable sources that are independent of the subject". Cunard (talk) 08:11, 2 March 2023 (UTC) 
 * I am not sure. I am neutral so far. @Cunard Those articles do not examine the journal, they examine articles published on the journal.GNC states: "Significant coverage" addresses the topic directly and in detail" Cinadon36</b> 10:04, 3 March 2023 (UTC)
 * I consider journal articles evaluating the body of work a journal publishes to be significant coverage of that journal's output and practices so allow the journal to meet Notability. Cunard (talk) 10:17, 3 March 2023 (UTC)


 * Keep - I found some papers discussing the journal with Baidu Xueshu. I don't have access to any of these, but they should be enough for notability. Mucube (talk • contribs) 01:24, 4 March 2023 (UTC)
 * Keep agree per above editors. Taung Tan (talk) 18:21, 8 March 2023 (UTC)


 * The above discussion is preserved as an archive of the debate. <b style="color:red">Please do not modify it.</b> Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.